| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/17/2013 | WO2013009165A1 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine |
| 01/17/2013 | WO2013008928A1 Macrolide derivative |
| 01/17/2013 | WO2013008803A1 Method for producing pluripotent cell using bacterium having fermentation ability |
| 01/17/2013 | WO2013008175A1 Method for producing trans-resveratrol and the analogs thereof |
| 01/17/2013 | WO2013008095A1 Novel pyrrolo pyrimidine derivatives |
| 01/17/2013 | WO2013007801A1 Predictive tool for response to anti-igf-1r antibody therapy in cancer patients |
| 01/17/2013 | WO2013007768A1 Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| 01/17/2013 | WO2013007708A1 Medicament for treatment of liver cancer |
| 01/17/2013 | WO2013007676A1 Aminomethyl quinolone compounds |
| 01/17/2013 | WO2013007663A1 2-benzylsulfanyl[1,3,4]-oxadiazole derivatives, and medical use thereof |
| 01/17/2013 | WO2013007660A1 Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
| 01/17/2013 | WO2013007387A1 Novel fxr (nr1h4) binding and activity modulating compounds |
| 01/17/2013 | WO2013007384A1 Use of lipoteichoic acid in the treatment of non-encapsulated cancer cells |
| 01/17/2013 | WO2013007383A1 Use of lipoteichoic acid in the treatment of cancer in an inflammatory state |
| 01/17/2013 | WO2013007184A1 Antineoplastic drug tetrahydronaphthalene amide-group compound and pharmaceutically acceptable salt, preparation method and use thereof |
| 01/17/2013 | WO2013007172A1 Platinum compounds for treating cell proliferative disease, preparation methods and uses thereof |
| 01/17/2013 | WO2013007053A1 Fully human antibodies against human vegf |
| 01/17/2013 | WO2013007052A1 Fully human antibodies against human cd20 |
| 01/17/2013 | WO2013006972A1 Novel anti-cancer isocarbostyril alkaloid conjugates |
| 01/17/2013 | WO2012162307A3 Crosslinked polymer nano-assemblies and uses thereof |
| 01/17/2013 | WO2012162243A3 Anti-cgrp compositions and use thereof |
| 01/17/2013 | WO2012161539A3 Sirna for inhibiting the expression of bhrf1 and composition comprising same |
| 01/17/2013 | WO2012160450A3 Modular transport platform for targeted delivery of therapeutic agents |
| 01/17/2013 | WO2012158989A3 Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation |
| 01/17/2013 | WO2012150973A9 Compositions for regulating iron homeostasis and methods of using same |
| 01/17/2013 | WO2012149454A3 Tolerogenic synthetic nanocarriers coupled to cd1d-restricted antigens and methods of use |
| 01/17/2013 | WO2012145582A3 Methods and compositions for the specific inhibitions of egfr by double-stranded rna |
| 01/17/2013 | WO2012143382A3 Gpr177 as target and marker in tumors |
| 01/17/2013 | WO2012142256A3 Modulators of mitochondrial protein import |
| 01/17/2013 | WO2012142083A3 C1q/tnf-related protein 12 and compositions and methods of using same |
| 01/17/2013 | WO2012138599A3 Hepatocyte growth factor mimics as therapeutic agents |
| 01/17/2013 | WO2012135818A3 Cancer diagnostics, therapeutics, and drug discovery associated with macropinocytosis |
| 01/17/2013 | WO2012135697A3 Novel rho kinase inhibitors and methods of use |
| 01/17/2013 | WO2012134170A3 Composition for lung cancer treatment and composition for cosmetics containing rubiae radix extract |
| 01/17/2013 | WO2012068412A3 Method and compositions for treatment of stat3-responsive cancers and/or renal cancer |
| 01/17/2013 | WO2011082487A8 Bisphenol derivatives and their use as androgen receptor activity modulators |
| 01/17/2013 | US20130018299 Nanoshells on polymers |
| 01/17/2013 | US20130018103 Bifunctional histone deacetylase inhibitors |
| 01/17/2013 | US20130018096 Platinum complex with antitumor activity |
| 01/17/2013 | US20130018088 Methods and compositions for anti-egfr treatment |
| 01/17/2013 | US20130018087 miRNA Compounds for Treatment of Prostate Carcinoma |
| 01/17/2013 | US20130018086 Sirnas targeting exon 10 of pyruvate kinase m2 |
| 01/17/2013 | US20130018085 iRNA Agents Targeting VEGF |
| 01/17/2013 | US20130018075 Heterocyclic inhibitors of mek and methods of use thereof |
| 01/17/2013 | US20130018072 Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase |
| 01/17/2013 | US20130018070 Modulators of cystic fibrosis transmembrane conductance regulator |
| 01/17/2013 | US20130018069 Sustained release delivery systems for the prevention and treatment of head and neck cancers |
| 01/17/2013 | US20130018067 Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
| 01/17/2013 | US20130018060 Inhibitors of bruton's tyrosine kinase |
| 01/17/2013 | US20130018057 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors |
| 01/17/2013 | US20130018054 New compounds |
| 01/17/2013 | US20130018052 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
| 01/17/2013 | US20130018051 Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| 01/17/2013 | US20130018046 Acetylenic Heteroaryl Compounds |
| 01/17/2013 | US20130018045 New Chemical Entities To Be Used For Wee1 Inhibition For The Treatment Of Cancer |
| 01/17/2013 | US20130018043 Aminomethyl quinolone compounds |
| 01/17/2013 | US20130018042 Toll-Like Receptor Agonist Formulations and Their Use |
| 01/17/2013 | US20130018041 Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
| 01/17/2013 | US20130018038 Chemical compounds |
| 01/17/2013 | US20130018036 Substituted indazole derivatives active as kinase inhibitors |
| 01/17/2013 | US20130018035 Compounds useful as inhibitors of atr kinase |
| 01/17/2013 | US20130018034 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| 01/17/2013 | US20130018033 Raf inhibitor compounds and methods of use thereof |
| 01/17/2013 | US20130018032 Inhibitors of bruton's tyrosine kinase |
| 01/17/2013 | US20130018028 Bi-(indole-2-aceto)-iron II (Ferrous Indole Acetate) |
| 01/17/2013 | US20130018027 Compositions and methods for non-toxic delivery of antiprogestins |
| 01/17/2013 | US20130018026 Halogenated phenols for diagnostics, antioxidant protection and drug delivery |
| 01/17/2013 | US20130018025 Anticancer Compound |
| 01/17/2013 | US20130018017 Quinolinone derivatives as parp and tank inhibitors |
| 01/17/2013 | US20130018014 New class of therapeutics that enhance small molecule diffusion |
| 01/17/2013 | US20130018010 Polymeric conjugates of adenine nucleoside analogs |
| 01/17/2013 | US20130018002 Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles |
| 01/17/2013 | US20130018001 Methods of diagnosing cancer |
| 01/17/2013 | US20130017998 Novel modified galectin 9 proteins and use thereof |
| 01/17/2013 | US20130017996 Muteins of tear lipocalin and methods for obtaining the same |
| 01/17/2013 | US20130017600 Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| 01/17/2013 | US20130017565 Methods and products related to low molecular weight heparin |
| 01/17/2013 | US20130017275 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells |
| 01/17/2013 | US20130017273 Compounds useful as inhibitors of atr kinase |
| 01/17/2013 | US20130017272 Method for treating non-small cell lung cancer |
| 01/17/2013 | US20130017266 Radiation Therapy Agent |
| 01/17/2013 | US20130017265 Particles for multiple agent delivery |
| 01/17/2013 | US20130017258 Self-microemulsifying mitotane composition |
| 01/17/2013 | US20130017255 Tamper Resistant Dosage Form Comprising an Adsorbent and an Adverse Agent |
| 01/17/2013 | US20130017253 Inducing Cellular Immune Responses to Human Papillomavirus Using Peptide and Nucleic Acid Compositions |
| 01/17/2013 | US20130017225 Natural plant products for control of cancer metastasis |
| 01/17/2013 | US20130017222 Human prostate cell lines in cancer treatment |
| 01/17/2013 | US20130017210 Display of antibody fragments on virus-like particles of rna bacteriophages |
| 01/17/2013 | US20130017208 Anti-IL-6 Antibodies, Compositions, Methods and Uses |
| 01/17/2013 | US20130017207 Chemotherapeutic methods and compositions |
| 01/17/2013 | US20130017205 Inhibition of AXL Signaling in Anti-Metastatic Therapy |
| 01/17/2013 | US20130017200 Multispecific antibodies, antibody analogs, compositions, and methods |
| 01/17/2013 | US20130017199 Simultaneous inhibition of pd-l1/pd-l2 |
| 01/17/2013 | US20130017197 Stabilized antibody preparations and uses thereof |
| 01/17/2013 | US20130017196 Substituted imidazole derivatives |
| 01/17/2013 | US20130017194 Fak inhibitors |
| 01/17/2013 | US20130017189 Functionalised Triblock Copolymers and Compositions Containing Such Polymers |
| 01/17/2013 | US20130017183 Compositions containing non-polar compounds |
| 01/17/2013 | US20130017173 Novel compositions and methods for treating inflammatory bowel disease and airway inflammation |
| 01/17/2013 | US20130017172 Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus |